tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Premier (PINC) and Ultragenyx Pharmaceutical (RARE)

Analysts fell to the sidelines weighing in on Premier (PINCResearch Report) and Ultragenyx Pharmaceutical (RAREResearch Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Premier (PINC)

Robert W. Baird analyst Eric Coldwell maintained a Hold rating on Premier on July 18 and set a price target of $41.00. The company’s shares closed last Tuesday at $37.30.

According to TipRanks.com, Coldwell is a 5-star analyst with an average return of 8.1% and a 51.3% success rate. Coldwell covers the Healthcare sector, focusing on stocks such as AmerisourceBergen, Quest Diagnostics, and Cardinal Health.

Premier has an analyst consensus of Moderate Buy, with a price target consensus of $43.40.

See the top stocks recommended by analysts >>

Ultragenyx Pharmaceutical (RARE)

Robert W. Baird analyst Joel Beatty maintained a Hold rating on Ultragenyx Pharmaceutical on July 18 and set a price target of $90.00. The company’s shares closed last Tuesday at $52.89, close to its 52-week low of $45.20.

According to TipRanks.com, Beatty is a 4-star analyst with an average return of 3.2% and a 49.6% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, BioMarin Pharmaceutical, and TRACON Pharmaceuticals.

Ultragenyx Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $108.60, a 94.1% upside from current levels. In a report issued on July 14, Wedbush also maintained a Hold rating on the stock with a $70.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PINC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed